No excuses when LP continues to dilute in pennies throughout the year and asks for a 500M to 1B increase in authorized share count in the coming months.
Except you can't convince BP to be interested in NWBO and DCVax-L. They had years and years and have ALL passed on it. You should know that BPs don't do deals with OTC biotech drug companies -- haven't seen one in the last decade. Too many frauds in OTC world. They also can see the P3 trial history and all the protocol manipulations -- MAJOR RED FLAG. Don't be on it, it's not going to happen -- I worked with BP BizDev team and they won't even look at an OTC. ~600 major exchange biotechs to research and stay on top of. OTCs aren't worth the time.
Market Data 
Markets 
AI
